More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.

BACKGROUND: Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europe and estimated the number of patients without access to first-line recommended treatment per current guidelines of professional entities such as the European Society for Medical Oncology (ESMO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Association of Dermato-Oncology (EADO), and European Dermatology Forum (EDF). MATERIALS AND METHODS: Web-based online survey was conducted in 30 European countries with questions about the treatment schedules from 1st May 2015 to 1st May 2016: number of metastatic melanoma patients, registration and reimbursement of innovative medicines (updated data, as of 1st October 2016), percentage of patients treated and availability of clinical studies and compassionate-use programmes. RESULTS: The recommended BRAF inhibitor (BRAFi) + MEK inhibitor (MEKi) combination was both registered and fully reimbursed in 9/30 (30%) countries, and in 13/30 (43%) (all from Eastern Europe) not reimbursed. First-line immunotherapy with anti-PD1 antibodies was registered and fully reimbursed in 14/30 (47%) countries, while in 13/30 (43%) (all from Eastern Europe) not reimbursed. It was estimated that in Europe 19,600 patients with metastatic melanoma are treated, and 5238 (27%) do not have access to recommended first-line therapy. Significant correlation was found between human development index (HDI, UNDP report 2015), (r = 0.662; p < 0.001), health expenditure per capita (r = 0.695; p < 0.001) and the Mackenbach score of health policy performance (r = 0.765; p < 0.001) with the percentage of patients treated with innovative medicines and a number of reimbursed medicines. CONCLUSIONS: Great discrepancy exists in metastatic melanoma treatment across Europe. It is crucial to increase the awareness of national and European policymakers, oncological societies, melanoma patients' associations and pharma industry.

Bond strengths of two dental bonding systems.

A new bonding system named Kevloc has been introduced. It is based on acrylization of the metal surface with the goal of preventing the occurrence of a marginal gap between the metal and the resin. The purpose of this investigation was to determine the values of the shear bond strength achieved using the Kevloc technique on Ag-Pd (Auropal SE) and Co-Cr (Basil S) alloys and to compare them with those obtained with the OVS technique. The shear bond strengths were measured with the Smitz-Schulmayer shear test in a universal testing machine for polymer materials. A microscope image analyzer was used to measure the thickness of bonding layers and to reveal the possible occurrence of the marginal gap with both techniques. No marginal gap was detected with either technique. Kevloc provided better results than OVS only in a group of specimens tested after polymerization. Immersion in water and thermocycling reduced the initially high bond strength values of Kevloc specimens, whereas the bond strength values of OVS specimens remained unchanged regardless of which aging treatment was used. Microscopic examination did not reveal the existence of the marginal gap for either bonding system. According to the results obtained, it can be concluded that the Kevloc bonding system does not provide better shearing bond strength than the OVS bonding system.